Alex Melamed

Our latest lead by Dr. Katy Abel. More evidence that underutilization of NACT is associated with worse post-operative outcomes, without any hint of long-term benefit, even in high-volume centers.

Our JAMA Oncology study is now featured in the @IJGConline podcast! Thank you for highlighting our work. Grateful to work with such an amazing team! @dviverosc @headofmelon @NiteckiRoni @RParejaGineOnco @RauhHainMD

Our 15-year cohort study explores trends in surgical de-escalation in gynecologic oncology. These findings are transforming patient care but raise important questions about the preparation of fellows in surgical training. @headofmelon @dviverosc @RauhHainMD @NiteckiRoni

LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoreduction in ovarian cancer. @RauhHainMD @annafagottimd @RParejaGineOnco @pedroramirezMD @abedsinno

#cancer during #pregnancy is associated with severe maternal and neonatal morbidity. Proud of the entire team for this important manuscript! authors.elsevier.com/c/1k7m2gm3zE9I @RauhHainMD @headofmelon @markaclapp @abigailflynt @dviverosc @nagustiga @MDAndersonNews @AJOG_thegray

What an honor for us to host @scambiagiovanni and @annafagottimd at @MghObgyn.

Cool picture of a adenosarcoma assocaited uterine inversion which we treated laparoscopically. Nice work by Baran Vardar and @AlexBercowMD getting these pictures into the literature. pubs.rsna.org/doi/10.1148/ry…

Josseli Barnica is the victim of a totalitarian state imposing its ideology on women’s bodies. America we are better than this.

NACT and interval cytoreductive surgery edges out primary cytoreductive surgery as the most frequent treatment for advanced-stage ovarian cancer in the US. 11 years after Vergote et al. It really does take a decade.

Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US. ja.ma/4dNCjEa

Thanks @IJGConline and @pedroramirezMD for this great honor.

@cameron_pfiffer @arieda_muco

@arieda_muco It's just stats

Mhm yes. Logistic regression? A machine learning algorithm. Ok bud

@GeorgiaTomova @IntJEpidemiol Yikes

@ebonycartermd @UNC They are lucky to have you!

Our family is excited to begin the next leg of life's journey as Tar Heels @UNC !!!

After a wonderful decade @WashU_OBGYN @WUSTL that saw the birth of our 3 little 👧🏽's, lifelong friendships, and collaborations that are catalyzing positive change,@dedriccarter and I are heading back to the Carolinas! @UNCOBGYN med.unc.edu/intranet/2023/…

A new paper by super intern Katy Abel looks at the use and efficacy of primary site surgery in metastatic cancer. There is a lot of heterogeneity across cancer sites, raising essential questions about how, and if, we know when surgery is helpful onlinelibrary.wiley.com/doi/full/10.10…

A new paper by Jason Silberman @JSilby3: who is on the market for the gyn onc fellowship spot! tinyurl.com/2pzjm748 cytotoxic NACT has increased for stage III&IV low-grade serous ovarian cancer in last 15y w/o evidence that this approach is effective in this cancer type

@s_j_prins "he does not share our beliefs about the state's role in defining normative interpersonal relationships, therefore his ideas are suspect" is not a good argument. lots of statisticians and epidemiologists who had shitty beliefs still made useful contributions.

@s_j_prins like Vanderweele's stuff or not, his beliefs re: gay marriage (as much as you and I may find them to be reprehensible) have nothing to do with the argument he and others have made about how to formalize and operationalize ideas about causation. This kind of argument is lame.